U
TPST icon

UBS’s Tempest Therapeutics TPST Stock Holding History

UBS’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$64K Hold
1
– – ﹤0.01% 6533
2014
Q2 		$38K Hold
1
– – ﹤0.01% 7247
2014
Q1 		$35K Hold
1
– – ﹤0.01% 7323
2013
Q4 		$20K Hold
1
– – ﹤0.01% 8160
2013
Q3 		$28K Hold
1
– – ﹤0.01% 7630
2013
Q2 		$33K Buy
+1
New +$37.6K ﹤0.01% 7272

Other funds holding TPST

DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

UBS's TPST Position: Q3 2014 in Review

UBS held its Tempest Therapeutics (TPST) position steady in Q3 2014 at 1 share worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #6533.

UBS first reported a position in TPST in Q2 2013 and has held it in 6 quarters since. 53 funds tracked by Wall St. Rank hold TPST as of Q3 2014.

  • UBS held 1 share of Tempest Therapeutics worth $64K as of Q3 2014.
  • UBS left its Tempest Therapeutics share count unchanged in Q3 2014.
  • Tempest Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6533 holding.
  • UBS first reported a position in Tempest Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • 53 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.